Comparison of the effect on vascular endothelial function and systemic metabolism between Liraglutide and insulin Glargine in patients with type 2 diabetes -prospective randomized controlled trial-

Comparison of the effect on vascular endothelial function and systemic metabolism between Liraglutide and insulin Glargine in patients with type 2 diabetes -prospective randomized controlled trial- - Study for the effects of Liraglutide on vascular endothelial function and systemic metabolism in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005331

Enrollment

Registered

2011-03-28

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Liraglutide Insulin Glargine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients with type 2 diabetes using glimepiride (0.5mg-2mg) and/or metformin and/or DPP-4 inhibitor, 2) HbA1c 7.4-10.5% (NGSP), 3) blood pressure and lipids are well controlled 4) written informed consent

Exclusion criteria

Exclusion criteria: 1) patients who received insulin injection therapy, 2) severe hepatic dysfunction, renal dysfunction, heart failure, 3) history of angina, myocardial infarction, stroke or other arteriosclerotic diseases, 4) patients who receive more than three antihypertensive agents, 5) patients who receive more than two antidyslipidemia agents, 6) history of anaphylaxis of liragrutide or insulin glargine, 7) pregnancy, 8) patients who are inadequate to enter this study due to the other reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Change in FMD (Flow mediated dilatation)	—

Secondary

Measure	Time frame
1) glucose and lipid metabolism, 2) beta cell function, 3) changes in TBI(Toe-brachial index) and Task force monitor, 4) several biomarkers (adipokines, oxidative stress, etc)	—

Countries

Japan

Contacts

Public ContactHideaki Miyoshi

Hokkaido University Hospital Department of Internal Medicine II

hmiyoshi@med.hokudai.ac.jp011-706-5915

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026